Amgen and Novartis Sue Each Other After Migraine Deal Collapses
- Swiss drugmaker claims rival used ‘pretext’ to evade pacts
- It says Amgen wants to cut it out of future U.S. Aimovig sales
This article is for subscribers only.
Amgen Inc.’s multibillion-dollar collaboration with Novartis AG to jointly develop and market Amgen’s popular migraine-prevention treatment, Aimovig, triggered legal headaches for both companies in the U.S.
The drugmakers on Thursday filed separate lawsuits in Manhattan federal court, accusing each other of violating two collaboration agreements they struck in 2015 and 2017 to work together and divvy up sales across the globe of Aimovig, which was approved in the U.S. in 2018.